collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric DisordersThrough the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia.  The new collaboration further expands Boehringer Ingelheim ’s circuitry-based approach to precision psychiatry and solidifies the company’s commitment to provide better treatments for patients living with serious mental health conditions.
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news